SAB-176 is under clinical development by SAB Biotherapeutics and currently in Phase I for Influenzavirus B Infections. According to GlobalData, Phase I drugs for Influenzavirus B Infections have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SAB-176’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SAB-176 overview
SAB-176 is under development for the treatment of seasonal influenza, influenzavirus A H1N1 type and B infections, coronavirus disease 2019 (COVID-19). The therapeutic candidate constitutes polyclonal antibodies against four strains of influenza virus. It is developed based on Diversity platform that leverages transchromosomic cattle (Tc Bovine) which have been genetically designed to produce fully human antibodies (immunoglobulin G) in response to an antigen. It is administered through intravenous route.
See Also:
SAB Biotherapeutics overview
SAB Biotherapeutics is a healthcare service provider that develops and delivers technologies to transform the treatment and prevention of diseases from cancer and inflammation to autoimmune and influenza. The company offers pipeline products include MERS-CoV, MYCOPLASMA, commercial pipeline products, seasonal influenza, anti-thymocyte globulin, multivalent, and long term care products, among others. In addition, it also provides clinical studies underway and advancing immunotherapies for influenza, MERS-CoV, Ebola, alpha viruses, filo virus, dengue virus, and hantavirus and cancers. SAB Biotherapeutics creates antibodies to prevent and treat human conditions such as cancer, inflammation, autoimmune disorders, and infectious diseases and emerging global health threats. The company caters its products and services to healthcare, medical and pharmaceutical sectors. SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota, the US.
For a complete picture of SAB-176’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
